Article Text

PS-242 Rituximab In The Treatment Of Minimal Change Disease In Children With Nephrotic Syndrome
  1. XL Niu,
  2. S Hao,
  3. P Wang,
  4. GH Zhu,
  5. Y Wu,
  6. W Zhang,
  7. GM Guo,
  8. WY Huang
  1. Nephrology and Rheumatology, Shanghai Children’s Hospital Shanghai Jiaotong University, Shanghai, China


Background and aims To explore the efficiency and side effects of rituximab in the treatment of minimal change disease (MCD) in children with steriod-dependent nephrotic syndrome (SDNS).

Methods From 2011.10 to 2014.4, children with MCD who hospitalised alwaysrelapsed although treated with steroid and one or more immunosuppressants. Thenthey were given rituximab 1 or 2 times (375 mg/m2).

Results Fifteen patients (male: female 7:8)with MCD, ageing from 4–17 years old (7.93 ± 3.26 years old) were followed up for 2–30 months (15.4 ± 9.86 months). After infusion of rituximab, the B cell was obviously decreased (CD20 < 1%, T = 110, PT = 4, PT = 91, PT = 1, P Side effect: Only two patients got mildly uncomfortable in the infusion of rituximab but relieved with decreasing the rate of infusion.

Conclusion Rituximab has efficiency in treating children with MCD. It can help to reduce the dosage of steroids. And maybe one time of rituximab is enough for children with MCD. And there are no seriously side effects of rituximab.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.